---
title: "VXRT: Positive safety data, BARDA funding, and cash runway into Q2 2027 amid lower revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295157268.md"
description: "Q2 2026 saw positive safety data from the COVID-19 oral pill vaccine trial and additional BARDA funding, with revenue declining year-over-year and a net loss of $13.5M. Cash runway extends into Q2 2027, and topline efficacy data is expected in the first half of 2027.Original document: Vaxart, Inc. [VXRT] SEC 8-K Current Report — Aug. 7 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-06T23:45:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295157268.md)
  - [en](https://longbridge.com/en/news/295157268.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295157268.md)
generator: "portal-rs"
---

# VXRT: Positive safety data, BARDA funding, and cash runway into Q2 2027 amid lower revenue

Q2 2026 saw positive safety data from the COVID-19 oral pill vaccine trial and additional BARDA funding, with revenue declining year-over-year and a net loss of $13.5M. Cash runway extends into Q2 2027, and topline efficacy data is expected in the first half of 2027.

Original document: Vaxart, Inc. \[VXRT\] SEC 8-K Current Report — Aug. 7 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VXRT.US](https://longbridge.com/en/quote/VXRT.US.md)

## Related News & Research

- [AUB: Double-digit profit growth and margin expansion achieved, with strong FY 2027 outlook](https://longbridge.com/en/news/296849980.md)
- [NSSC: Record revenue, margin expansion, and recurring growth set stage for strong fiscal 2027](https://longbridge.com/en/news/296814968.md)
- [Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027](https://longbridge.com/en/news/296546698.md)
- [Allreal schedules 2027 annual general meeting](https://longbridge.com/en/news/296733691.md)
- [ABB: FY 2026 delivered robust growth, margin expansion, and strategic scale, with strong FY 2027 outlook](https://longbridge.com/en/news/296729552.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**